Ultomiris®
Understanding Ultomiris®
Ultomiris® is used to treat rare blood and immune system disorders by blocking the C5 complement protein. By inhibiting C5, Ultomiris® prevents the immune system from attacking healthy red blood cells, nerves, and blood vessels. This targeted approach helps reduce inflammation, hemolysis (destruction of red blood cells), and blood clot formation, making it an effective treatment option for conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
How Ultomiris® Works:
- Inhibits the C5 complement protein, preventing immune system overactivation.
- Reduces hemolysis and inflammation in PNH and aHUS.
- Prevents immune attacks on the nervous system, helping patients with gMG and NMOSD.
FDA Approvals:
- PNH: Approved on December 21, 2018
- aHUS: Approved on October 18, 2019
- gMG: Approved on April 28, 2022
- NMOSD: Approved on January 23, 2024
For more information, please visit the Ultomiris® patient website and speak with your healthcare provider to determine if Ultomiris® is the right treatment option for you.
Referral Form: |
MANUFACTURER: Alexion Pharmaceuticals, AstraZeneca Rare Disease |
CLASS: CD19-Directed Monoclonal Antibody |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion |
|
FREQUENCY: Two treatments, two weeks apart, then one every six months |
Length of infusion: Two hours in adults and up to four hours in children |
FOR MORE INFORMATION: |
Related drugs
